The stock price of Alto Neuroscience Inc (NYSE: ANRO) has plunged by -11.96 when compared to previous closing price of 2.57, but the company has seen a -0.33% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-26 that MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)—- $ANRO #PrecisionPsychiatry–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, h.
Is It Worth Investing in Alto Neuroscience Inc (NYSE: ANRO) Right Now?
The stock has a 36-month beta value of 1.97. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ANRO is 21.49M, and at present, short sellers hold a 13.00% of that float. On June 26, 2025, the average trading volume of ANRO was 255.36K shares.
ANRO’s Market Performance
ANRO stock saw a decrease of -0.33% in the past week, with a monthly decline of -21.16% and a quarterly a decrease of -9.50%. The volatility ratio for the week is 8.46%, and the volatility levels for the last 30 days are 7.90% for Alto Neuroscience Inc (ANRO). The simple moving average for the last 20 days is -8.07% for ANRO stock, with a simple moving average of -53.12% for the last 200 days.
Analysts’ Opinion of ANRO
Many brokerage firms have already submitted their reports for ANRO stocks, with Wedbush repeating the rating for ANRO by listing it as a “Neutral.” The predicted price for ANRO in the upcoming period, according to Wedbush is $4 based on the research report published on October 23, 2024 of the previous year 2024.
Wedbush gave a rating of “Outperform” to ANRO, setting the target price at $29 in the report published on September 03rd of the previous year.
ANRO Trading at -7.76% from the 50-Day Moving Average
After a stumble in the market that brought ANRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANRO starting from Savitz Adam, who purchase 12,069 shares at the price of $12.60 back on Jul 09 ’24. After this action, Savitz Adam now owns 36,920 shares of Alto Neuroscience Inc, valued at $152,085 using the latest closing price.
Savitz Adam, the CHIEF MEDICAL OFFICER of Alto Neuroscience Inc, purchase 2,931 shares at $13.22 during a trade that took place back on Jul 10 ’24, which means that Savitz Adam is holding 39,851 shares at $38,748 based on the most recent closing price.
Stock Fundamentals for ANRO
The total capital return value is set at -0.42. Equity return is now at value -38.04, with -33.09 for asset returns.
Based on Alto Neuroscience Inc (ANRO), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -12.01. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -162.18.
Currently, EBITDA for the company is -68.61 million with net debt to EBITDA at 2.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.53.
Conclusion
To sum up, Alto Neuroscience Inc (ANRO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
